[An analysis of double autologous hemopoietic stem cell transplantation for hematological malignancies].
OBJECTIVE
To analyse the clinical efficacy of the double autologous hemopoietic stem cell transplantation (DAHSCT) for hematological malignancies.


METHODS
19 hematological malignant disease patients received the first AHSCT within 12 months after diagnosis. The first conditioning regimen was VP-16 or Ara-C, CTX +, TBI, nine of them received BCNU additionally. All patients received the second AHSCT in 4 to 10 months after the first AHSCT. The second conditioning regimen was VP-16 (or Ara-C), CTX +, Mel.


RESULTS
All patients had rapidly hemopoietic reconstitution, the first hemopoietic reconstitution is faster than the second. There was no AHSCT related death. The median follow up duration was 1078 days. 12 of the 19 patients were still alive during the analysis. The 3-year disease-free suvival (DFS) was 63% +/- 10%. Those patients who had more blasts in bone marrow at the second AHSCT than the first AHSCT had greater probability to relapse.


CONCLUSIONS
DAHSCT can be safety performed as an important treatment method in hematological malignancies.
Zhang
Bolong
B
Department of Hematology the PLA General Hospital of People's Liberation Army of China, Beijing 100853, China.
Huang
Wenrong
W
Da
Wanming
W
Zhang
Zhanqiang
Z
Yao
Shanqian
S
Gao
Chunji
C
Han
Xiaoping
X
Wu
Xiaoxiong
X
Wang
Quanshun
Q
Yu
Li
L
Zhang
Miao
M
Jin
Haijie
H
D000293:Adolescent; D000328:Adult; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome